Comparison of Leap Therapeutics Inc. (LPTX) and Aerpio Pharmaceuticals Inc. (NASDAQ:ARPO)

Leap Therapeutics Inc. (NASDAQ:LPTX) and Aerpio Pharmaceuticals Inc. (NASDAQ:ARPO) are two firms in the Biotechnology that compete against each other. Below is a comparison of their risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Leap Therapeutics Inc. 1 0.19 14.39M -1.32 0.00
Aerpio Pharmaceuticals Inc. 1 0.00 25.16M -0.36 0.00

Table 1 shows the gross revenue, earnings per share and valuation for Leap Therapeutics Inc. and Aerpio Pharmaceuticals Inc.


Table 2 hightlights the net margins, return on equity and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
Leap Therapeutics Inc. 1,407,747,994.52% -190.9% -80.5%
Aerpio Pharmaceuticals Inc. 4,715,142,428.79% -20.5% -17.7%


Leap Therapeutics Inc.’s Current Ratio and Quick Ratio are 2.8 and 2.8 respectively. The Current Ratio and Quick Ratio of its competitor Aerpio Pharmaceuticals Inc. are 13.8 and 13.8 respectively. Aerpio Pharmaceuticals Inc. therefore has a better chance of paying off short and long-term obligations compared to Leap Therapeutics Inc.

Institutional and Insider Ownership

Institutional investors owned 40% of Leap Therapeutics Inc. shares and 23.4% of Aerpio Pharmaceuticals Inc. shares. About 13.26% of Leap Therapeutics Inc.’s share are owned by insiders. Competitively, Aerpio Pharmaceuticals Inc. has 1.1% of it’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Leap Therapeutics Inc. 17.1% 29.89% 32.94% 3.91% -69.79% 13%
Aerpio Pharmaceuticals Inc. 0.13% -8.73% -22.06% -79.51% -80.37% -53.24%

For the past year Leap Therapeutics Inc. had bullish trend while Aerpio Pharmaceuticals Inc. had bearish trend.


Aerpio Pharmaceuticals Inc. beats on 7 of the 10 factors Leap Therapeutics Inc.

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapeutics in cancer biology. Its clinical stage programs include DKN-01, a monoclonal antibody targeting Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric and biliary tract cancers, as well as in Phase I clinical trial in patients with non-small cell lung cancer; and TRX518, a monoclonal antibody that is in Phase I clinical trial targeting the glucocorticoid-induced tumor necrosis factor-related receptor in patients with solid tumors. Leap Therapeutics, Inc. has a clinical trial collaboration agreement with Merck & Co., Inc. to investigate LeapÂ’s DKK1 antagonist, DKN-01, in combination with MerckÂ’s anti-PD-1 therapy, KEYTRUDA, in patients with relapsed or refractory advanced esophagogastric cancers. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company is headquartered in Cincinnati, Ohio. Aerpio Pharmaceuticals, Inc.(OTCPK:ARPO) operates independently of Akebia Therapeutics, Inc. as of December 22, 2011.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.